TQB2102-II-04
A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma
- NCT06767800 ↗
- Recruiting
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Focused
We haven't built an HCP commentary report on TQB2102-II-04 (Gastroesophageal Adenocarcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TQB2102-II-04 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Phase II Clinical Trial Evaluating the Efficacy and Safety of TQB2102 for Injection in Chemotherapy With Behmosubstituted Monoclonalb/Pembrolizumab ± Chemotherapy in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic HER2-Positive Gastroesophageal Adenocarcinoma
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Gastroesophageal Adenocarcinoma
- Interventions
- TQB2102 for injection (7.5 mg) +Benmelstobart+Chemotherapy; TQB2102 for injection (6 mg/7.5 mg) +Benmelstobart+Chemotherapy; TQB2102 for injection (6 mg/7.5 mg) +Penpulimab+Chemotherapy
- Arms
- TQB2102 for injection (7.5 mg) +Benmelstobart+Chemotherapy · Experimental
- TQB2102 for injection (6 mg/7.5 mg) +Benmelstobart+Chemotherapy · Experimental
- TQB2102 for injection (6 mg/7.5 mg) +Penpulimab+Chemotherapy · Experimental
- Enrollment
- 204 (estimated)
- Primary outcomes
- Objective Response Rate (ORR)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Start
- Nov 21, 2024
- Primary completion
- Sep 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06767800 · updated Jul 30, 2025